



GE Healthcare

251 Locke Drive
Marlborough, MA 01752
USA

www.gehealthcare.com

The Honorable Anna Eshoo
272 Cannon HOB
Washington, D.C. 20515

The Honorable Brett Guthrie
2434 Rayburn HOB
Washington, D.C. 20515

The Honorable Frank Pallone
2107 Rayburn HOB
Washington, D.C. 20515

The Honorable Cathy McMorris Rodgers
1035 Longworth HOB
Washington, D.C. 20515

Dear Representatives:

As a leading manufacturer of contrast imaging agents and diagnostic radiopharmaceuticals, I write to thank you for the inclusion of Section 803 in H.R. 7667, the Food and Drug Amendments of 2022. This provision clarifies that contrast agents and diagnostic radiopharmaceuticals are drugs under the Federal Food, Drug, and Cosmetic Act. GE Healthcare strongly supports this language.

GE Healthcare's Pharmaceutical Diagnostics business develops and supplies imaging agents used to support around 100 million procedures per year globally, the equivalent of three patient procedures every second worldwide. These imaging agents are used across MRI, CT, X-ray, ultrasound and nuclear medicine imaging to enhance the image and support diagnosis.

The statutory and accompanying regulatory certainty which this provision ensures is important for innovators such as GE Healthcare. It will allow us to bring new products through the established regulatory pathway to better serve patients and their healthcare provider.

GE Healthcare believes that contrast imaging agents should not be regulated differently depending on how the contrast imaging agent is administered. It is important to note that GE Healthcare manufactures a product which can be administered either orally or via injection.

GE Healthcare appreciates the inclusion of Section 803 in H.R. 7667. Our employees across the United States work hard every day to bring cutting-edge technologies and digital health solutions to American patients and patients all over the world. We truly appreciate your leadership on this important issue for our country.

Sincerely,

A handwritten signature in blue ink, appearing to read 'Marco Campione', written over a blue horizontal line.

Marco Campione
General Manager for Pharmaceutical Diagnostics in the Americas

As a leading global medical technology, pharmaceutical diagnostics and digital solutions innovator, GE Healthcare enables clinicians to make faster, more informed decisions through intelligent devices, data analytics, applications and services, supported by its Edison intelligence platform. With over 100 years of healthcare industry experience and around 48,000 employees globally, the company operates at the center of an ecosystem working towards precision health, digitizing healthcare, helping drive productivity and improve outcomes for patients, providers, health systems and researchers around the world.